Tags

Type your tag names separated by a space and hit enter

Clinical potential of minocycline for neurodegenerative disorders.

Abstract

Minocycline, an antibiotic of the tetracycline family, has been shown to display neurorestorative or neuroprotective properties in various models of neurodegenerative diseases. In particular, it has been shown to delay motor alterations, inflammation and apoptosis in models of Huntington's disease, amyotrophic lateral sclerosis and Parkinson's disease. Despite controversies about its efficacy, the relative safety and tolerability of minocycline have led to the launching of various clinical trials. The present review summarizes the available data supporting the clinical testing of minocycline for these neurodegenerative disorders. In addition, we extend our discussion to the potential applications of minocycline for combining this treatment with cellular and molecular therapy.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Laboratory of Experimental Neurosurgery, ULB-Erasme, 1070 Brussels, Belgium. David.Blum@ulb.ac.be

    , , ,

    Source

    Neurobiology of disease 17:3 2004 Dec pg 359-66

    MeSH

    Animals
    Apoptosis
    Humans
    Huntington Disease
    Inflammation
    Minocycline
    Motor Neuron Disease
    Neurodegenerative Diseases
    Neuroprotective Agents
    Parkinson Disease

    Pub Type(s)

    Journal Article
    Research Support, Non-U.S. Gov't
    Review

    Language

    eng

    PubMed ID

    15571972

    Citation

    Blum, David, et al. "Clinical Potential of Minocycline for Neurodegenerative Disorders." Neurobiology of Disease, vol. 17, no. 3, 2004, pp. 359-66.
    Blum D, Chtarto A, Tenenbaum L, et al. Clinical potential of minocycline for neurodegenerative disorders. Neurobiol Dis. 2004;17(3):359-66.
    Blum, D., Chtarto, A., Tenenbaum, L., Brotchi, J., & Levivier, M. (2004). Clinical potential of minocycline for neurodegenerative disorders. Neurobiology of Disease, 17(3), pp. 359-66.
    Blum D, et al. Clinical Potential of Minocycline for Neurodegenerative Disorders. Neurobiol Dis. 2004;17(3):359-66. PubMed PMID: 15571972.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Clinical potential of minocycline for neurodegenerative disorders. AU - Blum,David, AU - Chtarto,Abdelwahed, AU - Tenenbaum,Liliane, AU - Brotchi,Jacques, AU - Levivier,Marc, PY - 2004/03/26/received PY - 2004/07/01/revised PY - 2004/07/20/accepted PY - 2004/12/2/pubmed PY - 2005/3/8/medline PY - 2004/12/2/entrez SP - 359 EP - 66 JF - Neurobiology of disease JO - Neurobiol. Dis. VL - 17 IS - 3 N2 - Minocycline, an antibiotic of the tetracycline family, has been shown to display neurorestorative or neuroprotective properties in various models of neurodegenerative diseases. In particular, it has been shown to delay motor alterations, inflammation and apoptosis in models of Huntington's disease, amyotrophic lateral sclerosis and Parkinson's disease. Despite controversies about its efficacy, the relative safety and tolerability of minocycline have led to the launching of various clinical trials. The present review summarizes the available data supporting the clinical testing of minocycline for these neurodegenerative disorders. In addition, we extend our discussion to the potential applications of minocycline for combining this treatment with cellular and molecular therapy. SN - 0969-9961 UR - https://www.unboundmedicine.com/medline/citation/15571972/Clinical_potential_of_minocycline_for_neurodegenerative_disorders_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0969-9961(04)00165-2 DB - PRIME DP - Unbound Medicine ER -